With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.90319-52-1,(R)-4-Phenyloxazolidin-2-one,as a common compound, the synthetic route is as follows.
n-butyllithium (2.5 Min hexane, 13.5 mL, 33.74 mmol, 1.1 eq) was added to a solutionof (R)-4-phenyloxazolidin-2-one (5 g, 30.67 mmol, 1 eq) in dry THF (75 mL) at -50 ‘C under N2atomosphere. After 30 minutes, 2-fuoropropanoyl chloride (3.75 g, 33.74 mmol) was added, and thesolution was stirred for 1 hat -50 ‘C to -60 ‘C. The reaction was then quenched with a saturatedsolution ofNH4Cl, extracted with EtOAc, washed with NaHC03(sat), brine and dried over MgS04?Solvents were removed under reduced pressure. The product was purified over silica (hexane/EtOAc) and recovered as a brown oil (4 g, 55percent). 1H-NMR(CDCl3, 400 MHz): 8 7.35-7.21 (m, 5H), 5.99-5.84 (md, 1 H), 5.42-5.33 (dd, 1 H), 4.72 (dd, 1 H), 4.31(m, 1 H), 1.50 (m, 3 H)., 90319-52-1
As the paragraph descriping shows that 90319-52-1 is playing an increasingly important role.
Reference£º
Patent; PHARMARESOURCES (SHANGHAI) CO., LTD.; CHEN, Ping; PENG, Shaoping; LI, Yinqiang; LI, Dafeng; DONG, Xuejun; (48 pag.)WO2018/32356; (2018); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem